The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.

<h4>Background</h4>Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012. The present study aimed to assess the effectiveness, safety profile, and persistence to fingolimod in...

Full description

Bibliographic Details
Main Authors: Tamás Biernacki, Dániel Sandi, Judit Füvesi, Zsanett Fricska-Nagy, Tamás Zsigmond Kincses, Péter Ács, Csilla Rózsa, Enikő Dobos, Botond Cseh, László Horváth, Zsuzsanna Nagy, Attila Csányi, Krisztina Kovács, Tünde Csépány, László Vécsei, Krisztina Bencsik, on the behalf of the study investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0267346

Internet

https://doi.org/10.1371/journal.pone.0267346

Similar Items